Trials / Completed
CompletedNCT00878670
Investigation of Efficacy and Safety of EPOGAM
Prospective Clinical Trial to Assess the Efficacy and Safety of EPOGAM 1000 in Patients With Atopic Dermatitis (Explorative Pilot Study)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Max Zeller Soehne AG · Industry
- Sex
- All
- Age
- 2 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
In this study it will be investigated if patients with atopic dermatitis responding to EPOGAM treatment, show a significant increase of dihomo-gamma-linolic acid in the blood.
Detailed description
Patients with atopic dermatitis will receive EPOGAM 1000 for 12 weeks. Clinical symptoms of the disease will be assessed using the SCORAD score. Dihomo-gamma-linolic acid levels in the blood will be measured with GC-MS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EPOGAM 1000 | One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks. |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2009-04-09
- Last updated
- 2012-01-26
Locations
2 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00878670. Inclusion in this directory is not an endorsement.